Wegovy vs Ozempic vs Compounded Semaglutide: What's the Difference?
Short answer: Wegovy, Ozempic, and compounded semaglutide all contain the same active drug — semaglutide. The differences are FDA indication, dosing, price, and how you get them. Here's exactly what separates them and which option makes the most sense for you.
Updated April 2026 · Based on FDA prescribing information and current market pricing
Quick Answer
Wegovy
FDA-approved for weight loss
$1,349/mo list price
Max dose: 2.4 mg/week
Ozempic
FDA-approved for diabetes
$935/mo list price
Max dose: 2.0 mg/week
Compounded
Not FDA-approved (product)
$150–$350/mo
Flexible dosing
They're All Semaglutide — Same Drug, Different Labels
This is the most important thing to understand: Wegovy, Ozempic, and compounded semaglutide all contain the exact same molecule — semaglutide. It's a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and helps your body regulate blood sugar.
The confusion comes from the fact that Novo Nordisk (the manufacturer) sells semaglutide under two different brand names for two different FDA-approved uses:
- Ozempic — approved in 2017 for type 2 diabetes management
- Wegovy — approved in 2021 specifically for chronic weight management
Compounded semaglutide entered the picture during the 2022-2024 shortage, when licensed compounding pharmacies began producing their own semaglutide formulations to meet demand.
Wegovy vs Ozempic vs Compounded: Full Comparison
Wegovy: The Weight Loss–Approved Option
Wegovy is Novo Nordisk's semaglutide product specifically developed and FDA-approved for chronic weight management. It was approved in June 2021 for adults with a BMI of 30+ (or 27+ with at least one weight-related condition).
Wegovy Pros
- FDA-approved for weight loss — the only semaglutide product with this specific indication
- Higher max dose (2.4 mg) — optimized for maximum weight loss effect
- Structured titration schedule — gradual dose increases over 16 weeks minimize side effects
- Proven cardiovascular benefits — SELECT trial showed 20% reduction in heart attack/stroke risk
- Pre-filled pen — easy to use, no measuring required
Wegovy Cons
- Expensive — $1,349/month list price without insurance
- Limited insurance coverage — many plans still don't cover weight loss medications
- Supply shortages — availability has been inconsistent since launch
- Requires in-person or telehealth prescription
Ozempic: The Diabetes Drug Used Off-Label for Weight Loss
Ozempic was approved in 2017 for type 2 diabetes. It became famous for weight loss after patients and doctors noticed significant weight reduction as a "side effect." Many physicians now prescribe Ozempic off-label specifically for weight loss.
Ozempic Pros
- Better insurance coverage — more plans cover it (diabetes indication)
- Longer track record — approved since 2017, more real-world data
- Effective for weight loss — 12-14% average body weight loss even at lower doses
- Same semaglutide molecule — identical mechanism of action
Ozempic Cons
- Lower max dose (2.0 mg) — slightly less weight loss potential than Wegovy's 2.4 mg
- Off-label for weight loss — insurance may deny if prescribed specifically for weight management
- Still expensive — $935/month without insurance
- Supply shortages — same availability issues as Wegovy
Important Note: Using Ozempic for weight loss when you don't have diabetes is considered "off-label" use. This is legal and common, but some insurance companies will only cover Ozempic with a diabetes diagnosis.
Compounded Semaglutide: The Affordable Alternative
Compounded semaglutide is produced by licensed compounding pharmacies (typically FDA-regulated 503B outsourcing facilities). It uses the same semaglutide molecule but is not manufactured by Novo Nordisk and is not FDA-approved as a finished product.
It became widely available during the 2022-2024 semaglutide shortage, when the FDA allowed compounding pharmacies to produce copies of drugs on the shortage list.
Compounded Semaglutide Pros
- Much more affordable — $150-$350/month, up to 80% cheaper than brand-name
- Widely available — no shortage issues, available through many telehealth providers
- No insurance needed — cash-pay pricing is already affordable
- Flexible dosing — providers can customize doses
- Includes medical supervision — telehealth providers include consultations in the price
Compounded Semaglutide Cons
- Not FDA-approved as a product — the molecule is the same, but the finished product hasn't gone through FDA review
- Regulatory uncertainty — availability depends on the FDA shortage list status
- Quality varies by pharmacy — important to use providers that source from licensed 503B facilities
- Vial and syringe — some providers use vials instead of convenient pre-filled pens
Looking for Affordable Semaglutide?
We've compared the top telehealth providers offering compounded semaglutide, including pricing, medical supervision, and pharmacy quality.
Which Should You Choose? It Depends on Your Situation
Choose Wegovy if:
- Your insurance covers it
- You want the FDA-approved weight loss product
- You want the highest approved dose (2.4 mg)
- You have cardiovascular risk factors
Choose Ozempic if:
- You have type 2 diabetes (or your doctor recommends it)
- Your insurance covers Ozempic but not Wegovy
- Wegovy is unavailable due to shortages
Choose Compounded Semaglutide if:
- You don't have insurance or your plan doesn't cover GLP-1 medications
- Cost is a primary concern ($150-$350/mo vs $900-$1,350/mo)
- Brand-name versions are out of stock at your pharmacy
- You want to start treatment quickly through telehealth
Dosing Schedule Comparison
All three forms of semaglutide are injected once weekly. However, the titration schedules differ slightly:
Key Difference: Wegovy reaches a higher maintenance dose (2.4 mg vs 2.0 mg for Ozempic), which is why clinical trials showed slightly more weight loss with Wegovy. Compounded semaglutide dosing is typically set by your prescribing physician and can be customized.
Do Side Effects Differ Between the Three?
Since all three contain semaglutide, the side effects are essentially the same:
- Nausea (most common, ~44% of patients)
- Diarrhea (~30%)
- Constipation (~24%)
- Vomiting (~24%)
- Stomach pain (~20%)
Side effects are dose-dependent — they tend to be more pronounced at higher doses. Since Wegovy goes to 2.4 mg (vs Ozempic's 2.0 mg max), some patients may experience slightly more side effects at Wegovy's highest dose.
For a detailed breakdown of what to expect and how to manage symptoms, see our complete semaglutide side effects guide.
Will Compounded Semaglutide Still Be Available in 2026?
This is one of the most asked questions right now. Here's the current situation:
- FDA shortage list: Compounding pharmacies can produce semaglutide while it remains on the FDA's drug shortage list
- Novo Nordisk's position: The company has been pushing to end the shortage designation, which would restrict compounders
- Legal challenges: Several compounding pharmacy associations have filed legal challenges to protect patient access
- Current status (April 2026): Compounded semaglutide remains available, but the regulatory environment is uncertain
Our Advice: If you're considering compounded semaglutide, don't let regulatory uncertainty stop you from starting. The treatment is currently legal, widely available, and supervised by licensed physicians. If regulations change, your provider can help you transition to an alternative.
Frequently Asked Questions
Is Ozempic the same as Wegovy?
Yes and no. Both contain semaglutide (the same active ingredient), but they are different products. Ozempic is FDA-approved for type 2 diabetes, while Wegovy is FDA-approved specifically for weight loss. Wegovy also reaches a higher maximum dose (2.4 mg vs 2.0 mg).
Can I use Ozempic for weight loss instead of Wegovy?
Yes, many doctors prescribe Ozempic off-label for weight loss. It contains the same semaglutide molecule. However, Wegovy goes to a higher dose (2.4 mg) optimized for weight loss, while Ozempic maxes out at 2.0 mg.
What is compounded semaglutide?
Compounded semaglutide is made by licensed compounding pharmacies using the same semaglutide molecule. It costs significantly less ($150–$350/month vs $1,000–$1,600/month for brand-name) and is available through telehealth providers without insurance.
Is compounded semaglutide safe?
Compounded semaglutide from licensed, FDA-regulated 503B compounding pharmacies uses the same active molecule as Wegovy and Ozempic. It is prescribed by licensed physicians and prepared under strict pharmacy standards. However, it is not FDA-approved as a finished product.
Why is Wegovy so much more expensive?
Wegovy's high price ($1,349/month) reflects Novo Nordisk's R&D investment, clinical trial costs, FDA approval process, and patent protection. Compounded semaglutide ($150–$350/month) is cheaper because compounding pharmacies don't bear those costs.
Which is better for weight loss?
All three contain semaglutide and produce similar weight loss. Wegovy is the only one FDA-approved for weight loss and reaches the highest dose. Ozempic is often easier to get through insurance. Compounded semaglutide is the most affordable option. The best choice depends on your insurance, budget, and doctor's recommendation.
Will compounded semaglutide be banned?
The FDA has been tightening regulations. If semaglutide is removed from the shortage list, compounders may lose the ability to produce it. As of April 2026, it remains available but the regulatory landscape is evolving.
Does insurance cover Wegovy or Ozempic for weight loss?
Coverage varies widely. Many plans cover Ozempic for diabetes but not weight loss. Wegovy coverage for weight loss is improving but still limited — roughly 40-50% of commercial plans offer some coverage. Medicare does not currently cover GLP-1 medications for weight loss alone.
Related Articles
Sources
1. Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 384(11), 989-1002.
2. U.S. FDA. Wegovy (semaglutide) Prescribing Information. 2021.
3. U.S. FDA. Ozempic (semaglutide) Prescribing Information. 2017 (updated 2024).
4. Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity (SELECT Trial). NEJM, 389(24), 2221-2232.
5. U.S. FDA Drug Shortage Database. Semaglutide injection products. Accessed April 2026.
